

cy National Cancer Biotechnology Information ("NCBI") website.

**In the Claims:**

Please cancel claims 1, 2 and 5-10 without prejudice. Applicant reserves the right to pursue cancelled subject matter in subsequent continuation and divisional applications.

Please add new claim 11 as follows:

11. (New) The substantially pure nucleic acid molecule of claim 3 wherein said nucleic acid molecule comprises the nucleic acid sequence shown as SEQ ID NO:5.

Please amend claims 3 and 4 as follows:

3. (Amended) A substantially pure nucleic acid molecule comprising a nucleic acid sequence that has greater than 95% sequence identity with the nucleic acid sequence shown as SEQ ID NO:5, wherein said nucleic acid molecule encodes a polypeptide that functions as a tumor suppressor molecule.

4. (Amended) A substantially pure tumor suppressor nucleic acid molecule encoding the amino acid sequence shown as SEQ ID NO:6.

**REMARKS**

The specification has been amended so that the legends to Figures 2 and 5 conform to the formal figures, attached herewith. Also, hyperlinks have been deleted from the specification and replaced with the identity of the website. Thus, no new matter is introduced by these amendments.

Claims 3 and 4 and 11 are pending in this application. The amendments raise no issue of new matter. Reference to the nucleic acid encoding a polypeptide that functions as a tumor suppressor molecule finds basis throughout the specification and in particular at page 6, lines 3-8. Support in the specification for specified percent of sequence identity (95) as recited in claims 3 is found at page 9, lines 14-21.